ContributorsPublishersAdvertisers

Sintilimab Improves Response, But Not Survival in Pancreatic Cancer

targetedonc.com
 2022-01-21

Cover picture for the articleSintilimab treatment in pancreatic cancer shows mixed efficacy results in the phase 3 CISPD3 trial. Sintilimab (Tyvyt), an anti–PD-1 monoclonal antibody, demonstrated improved objective response rate (ORR) and tolerable safety profile but did not show overall survival (OS) or progression-free survival (PFS) benefit in patients with metastatic or recurrent pancreatic adenocarcinoma...

www.targetedonc.com

Comments / 0

Comments / 0